What Is a PI-RADS 4 Lesion and the Next Steps?

A PI-RADS 4 lesion on a prostate MRI means the radiologist sees an area where clinically significant prostate cancer is considered likely, though not certain. Across large pooled analyses, roughly half to six out of ten men with a PI-RADS 4 finding are eventually diagnosed with clinically significant cancer after biopsy. That leaves a substantial minority whose lesion turns out to be benign. The standard next step is almost always a targeted biopsy, but what happens after that depends on lesion location, PSA levels, and the biopsy result itself.

What the PI-RADS Scale Actually Tells You

PI-RADS stands for Prostate Imaging Reporting and Data System, and it is a standardized way for radiologists to score suspicious areas on a prostate MRI. The scale runs from 1 to 5. A score of 1 means clinically significant cancer is very unlikely; a score of 5 means it is very likely. PI-RADS 4 sits in the “likely” zone. The current version, PI-RADS 2.1, was released in 2019 and refined the criteria radiologists use when reading prostate MRI, particularly for lesions in the transition zone (the inner part of the gland that tends to enlarge with age).¹ The score is assigned based on what the lesion looks like on specific MRI sequences, how large it is, and where in the prostate it sits.

What PI-RADS 4 does not tell you is whether you have cancer. It is a probability estimate based on imaging alone. The radiologist is saying: “This looks suspicious enough that a biopsy is warranted.” It is a triage tool, not a diagnosis.

How Often PI-RADS 4 Lesions Turn Out to Be Cancer

The numbers vary somewhat depending on the study population and biopsy method, but the overall picture is consistent. A systematic review and meta-analysis that pooled data from multiple studies found a cancer detection rate of about 52% at the individual lesion level and about 59% at the patient level for PI-RADS 4 findings.² A separate meta-analysis focusing specifically on clinically significant prostate cancer (the kind that is more likely to grow, spread, or need treatment) reported a positive predictive value of about 40% for PI-RADS 4.³ Another study found the rate of clinically significant cancer in PI-RADS 4 lesions to be around 60%.⁴

To put this in context, PI-RADS 3 lesions (equivocal) have cancer detection rates in the range of 16 to 20%, while PI-RADS 5 lesions (very likely) sit around 85 to 89%.² PI-RADS 4 occupies the middle ground: cancer is the most common outcome, but a benign result is not unusual. So if your biopsy comes back clean, that does not mean the MRI was wrong or that something was missed. It means you were in the roughly 40 to 50% of PI-RADS 4 cases where the suspicious appearance was caused by something other than significant cancer.

Why Biopsy Is Recommended Regardless of PSA Density

For lower PI-RADS scores, particularly PI-RADS 3, urologists often weigh additional factors before deciding whether to proceed with biopsy. PSA density (the total PSA divided by prostate volume) is one of those factors and can help separate men who are more or less likely to harbor significant cancer. For PI-RADS 4 and above, however, the cancer risk is high enough that biopsy is recommended regardless of what the PSA density shows. A systematic review that assessed this directly concluded that PI-RADS 4 or higher carried a clinically significant cancer risk of at least 40% across all PSA density levels, making it inappropriate to skip biopsy based on a low PSA density alone.⁵

That said, PSA density is not irrelevant. A separate analysis found that combining the PI-RADS score with PSA density improved the overall diagnostic accuracy for clinically significant cancer, with sensitivity above 92% and specificity above 91% when used together.⁶ PSA density can help your urologist set expectations and plan the biopsy strategy, even if it does not change the recommendation to biopsy in the first place.

How the Biopsy Works

If you have a PI-RADS 4 lesion, the biopsy will typically be an MRI-targeted biopsy, meaning the suspicious area seen on MRI is specifically sampled. In most centers this is done as an MRI/ultrasound fusion procedure, where software overlays the MRI images onto a live ultrasound to guide the biopsy needle directly into the lesion. Many urologists also perform systematic biopsies (sampling the gland broadly) at the same time, and there is good reason for that approach.

One study found that among men who had both targeted and systematic biopsies done together, about 12% had clinically significant cancer detected only on the systematic (random) cores, meaning the targeted biopsy alone would have missed it.⁷ Another large study confirmed that combining targeted and systematic biopsy detected about 10% more clinically significant cancers than systematic biopsy alone, while also slightly reducing the detection of very low-grade cancers that often do not need treatment.⁸ A third study showed that targeted biopsy caught cancer in cases where systematic biopsy missed it, and also upgraded the cancer grading in some men, meaning it revealed more aggressive disease than the random samples alone suggested.⁹ The takeaway is that the two approaches are complementary: targeted biopsy is better at characterizing the visible lesion, and systematic biopsy catches cancers that MRI did not see.

Transperineal Versus Transrectal Approach

The biopsy needle can reach the prostate through the rectum (transrectal) or through the perineum, the skin between the scrotum and the anus (transperineal). Both methods work, but the trend in urology is moving toward the transperineal approach. A matched-pair analysis found that transperineal biopsy had a higher detection rate for clinically significant cancer compared to transrectal biopsy (about 51% versus 36%).¹⁰

Infection risk is the other major difference. A randomized clinical trial (the PREVENT trial) found zero infections in the transperineal group compared to a 1.6% infection rate in the transrectal group, a small but meaningful difference when you consider how many biopsies are performed worldwide each year.¹¹ Other complication rates were similar between the two methods. If your center offers the transperineal approach, it is generally the preferred option, though transrectal biopsy remains common and safe for the vast majority of patients.

What Causes False Positives on MRI

Understanding why a PI-RADS 4 lesion can turn out to be benign helps put the whole process in perspective. On MRI, certain non-cancerous conditions look remarkably similar to prostate cancer. One analysis of 76 false-positive PI-RADS 4 cases found a range of benign findings: normal tissue, chronic inflammation with reactive changes and glandular atrophy, stromal proliferation consistent with benign prostatic hyperplasia (BPH), and high-grade prostatic intraepithelial neoplasia (HGPIN), which is a pre-cancerous condition but not cancer itself.¹²

Inflammation appears to be a particularly important driver of false positives. A study that specifically examined the relationship between prostatic inflammation and MRI accuracy found that high-grade inflammation roughly doubled the false-positive rate for PI-RADS 4 and 5 lesions compared to low-grade inflammation (about 58% false-positive rate versus 34%).¹³ Prostatitis, whether you have symptoms or not, can create areas that restrict water diffusion and enhance with contrast on MRI in ways that closely mimic cancer.

How Location and Size Affect What Happens Next

Not all PI-RADS 4 lesions carry the same risk, and this is where the nuance matters. The prostate has two main zones relevant to cancer detection: the peripheral zone (the outer shell, where most prostate cancers arise) and the transition zone (the inner region that enlarges with age as BPH develops). Transition zone lesions are harder to read on MRI because the background tissue is more heterogeneous, with BPH nodules creating a lumpy, variable appearance that can obscure or mimic cancer.

A study that looked specifically at PI-RADS 4 management found a dramatic difference by location. In the peripheral zone, unambiguous PI-RADS 4 lesions without complicating features like prostatitis yielded a 95% cancer rate (73% clinically significant). But transition zone PI-RADS 4 lesions with overlapping signs of stromal hyperplasia (BPH) showed cancer in only 11% of cases, with just 4% being clinically significant.¹⁴ Based on this, the authors recommended that peripheral zone PI-RADS 4 lesions should be biopsied and, if negative, re-biopsied, while transition zone lesions with BPH-like features could potentially be followed with repeat MRI instead of immediate re-biopsy.¹⁴

Lesion size also matters. One study found that the optimal size cutoff for predicting clinically significant cancer in PI-RADS 4 lesions was about 8.5 millimeters. Patients with lesions larger than that had roughly 2.3 times the risk of clinically significant cancer compared to those with smaller lesions.⁴

When the Biopsy Comes Back Negative

A negative biopsy after a PI-RADS 4 finding can feel like good news wrapped in uncertainty. You do not have cancer right now, but you still have an MRI that looked suspicious. The question becomes: was the biopsy truly negative, or did it miss something?

A study tracking what happened to patients with PI-RADS 4 and 5 lesions that initially came back negative on biopsy found that on follow-up MRI, more than a third of those lesions were downgraded to PI-RADS 1 or 2, meaning they no longer looked suspicious.¹⁵ For the remaining lesions that persisted, repeat biopsy was performed. This supports the general approach of follow-up MRI within a year or so after a negative biopsy in the setting of a PI-RADS 4 lesion, rather than either ignoring the finding entirely or rushing into another biopsy immediately.

A separate analysis reviewed why some PI-RADS 4 and 5 lesions yield negative biopsies. Among 90 confirmed false-positive cases, about 44% were considered overestimated on review, meaning a second-look radiologist scored them lower. In many cases, transition zone nodules had penetrated into the peripheral zone and were mistaken for peripheral zone cancers. Another group of lesions were borderline between PI-RADS 3 and 4, and a small number turned out to be granulomatous inflammation, which can look nearly identical to cancer on MRI.¹⁶

How Much Radiologists Agree on PI-RADS 4

One of the less-discussed aspects of the PI-RADS system is that radiologists do not always agree on the score. Reading prostate MRI is a skill that improves with volume and experience, and there is inherent subjectivity in deciding whether a lesion is a 3, a 4, or a 5. A study comparing six radiologists found moderate agreement when distinguishing PI-RADS 4 or higher from lower categories. The updated PI-RADS 2.1 criteria improved agreement in the peripheral zone compared to the older version 2, though agreement in the transition zone stayed about the same.¹⁷

A separate study examining radiologists with different levels of experience found overall good agreement on PI-RADS version 2 scoring.¹⁸ However, a study from non-high-volume centers showed only fair to moderate agreement between pairs of readers, with the range depending on which pair was compared.¹⁹ This is worth knowing because if your MRI was read at a center that does not interpret a high volume of prostate MRIs, a second opinion from a specialized uroradiologist could change the score up or down and potentially alter the management plan.

The Cost-Effectiveness Question

For men navigating insurance and out-of-pocket costs, the MRI-first pathway is generally considered good value. A cost-effectiveness analysis found that MRI-targeted biopsy compared with standard ultrasound-guided systematic biopsy in the initial biopsy setting was consistently cost-effective across published studies.²⁰ The picture was less clear for men undergoing a second (repeat) biopsy, where the economic analysis showed more variable results. If you are in a repeat-biopsy situation, ask your urologist about whether the targeted approach versus a standard systematic approach makes the most sense for your specific case.

Artificial Intelligence in Prostate MRI Reading

AI tools for reading prostate MRI are developing rapidly and are already in clinical use at some centers. A systematic review found that machine learning and deep learning algorithms can detect clinically significant prostate cancer and classify lesions according to PI-RADS scores at levels comparable to human radiologists.²¹ One large validation study tested an AI algorithm against an experienced radiologist and found that the algorithm identified 96% of participants with clinically significant cancer, compared to 98% for the radiologist, with no statistically meaningful difference between them.²²

Where AI may prove especially useful is in combining imaging data with other clinical variables. One study tested whether adding a deep learning model to PI-RADS scoring could improve cancer detection and found that models combining AI output with PI-RADS scores performed significantly better than PI-RADS alone at the patient level.²³ These tools are not replacing radiologists yet, but they are increasingly serving as a second set of eyes. For patients at centers where AI-assisted reading is available, it adds a layer of consistency that can help reduce the inter-reader variability discussed earlier.

What to Ask Your Urologist

If you have been told you have a PI-RADS 4 lesion, a few specific questions can help you understand your situation better and feel more in control of the process:

• Where is the lesion? A peripheral zone lesion carries different implications than a transition zone lesion, as outlined above. If the lesion is in the transition zone with features of BPH, it may be less worrisome than the overall PI-RADS 4 statistics suggest.
• How big is it? Lesions above roughly 8 to 9 millimeters are associated with higher cancer detection rates. A very small PI-RADS 4 lesion may be slightly more reassuring, though it still warrants biopsy.
• Who read the MRI? If the MRI was read at a general radiology practice rather than a high-volume prostate MRI center, consider asking whether a second read by a subspecialist is available.
• Will the biopsy be targeted, systematic, or both? The combination approach catches more clinically significant cancers.
• Is transperineal biopsy available? If your center offers both approaches, the transperineal route has a lower infection risk and potentially better sampling of certain prostate regions.
• What is the follow-up plan if the biopsy is negative? A negative biopsy does not close the book. Understanding whether you will have a follow-up MRI in 6 to 12 months helps you plan ahead and reduces anxiety about the unknown.

Getting a PI-RADS 4 result is understandably stressful, but it is also a situation where modern imaging and biopsy tools give your care team a well-defined path forward. About four to six out of ten men with this score end up with a clinically significant cancer diagnosis, which means treatment planning starts promptly when it is needed. For the rest, the biopsy provides genuine reassurance, and a clear follow-up plan keeps watch for anything the initial biopsy may have missed.